Lilly says Phase 3b ADtouch trial shows EBGLYSS beats placebo in hand and foot atopic dermatitis skin clearance at Week 16
Bitget2026/09/30 12:05- Eli Lilly reported Phase 3b ADtouch results for EBGLYSS in moderate-to-severe hand and foot atopic dermatitis.
- Late-breaking data will be presented at the EADV Congress running Sept. 30–Oct. 3 in Vienna.
- Treatment met key study goals, showing rapid skin clearing with meaningful relief in itch and pain versus placebo.
- Patient-reported satisfaction improved, supporting a broader value story beyond clinician-assessed skin outcomes.
- Lilly has submitted the findings to the FDA to support a potential label update for localized hand and foot disease.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Edges Higher as Treasury Yields, Dollar Ease -- Market Talk
Morgan Stanley is tactically bullish on BHP (BHP.US): Two major copper mine catalysts may ignite the stock price in the next two months
Morgan Stanley maintains an "Overweight" rating on BHP Group, with an "attractive" industry outlook, and sets a target price of AUD 69.00 for its shares listed in Australia.
Bank of England hawkish official: Growth exceeds expectations and employment is resilient, which precisely proves that further rate hikes are necessary.
Megan Greene, a policymaker at the Bank of England, stated that the UK's economic growth surpassing expectations and the resilience of the job market indicate that the Bank of England's efforts to curb inflation are still insufficient.
Crypto prices
More
